文献速递中毒与环境急症心脑血管急症

替格瑞洛中毒后致死性脑出血:亟需特异性拮抗剂

Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed.
PubMed 文献 · Clin Toxicol (Phila) · 2018-06-11
一句话结论替格瑞洛大量摄入后血小板抑制持续,反复输注血小板无效,可致致死性脑出血,作者认为亟需特异性拮抗剂。

本文报告一例47岁男性在大量摄入替格瑞洛4天后,因跌倒和颅脑创伤继发严重脑出血死亡。入院后2天和3天分别评估ADP诱导的血小板聚集和血小板VASP磷酸化,均显示血小板抑制持续存在;反复输注血小板未改善病情。摄入后10小时LC-MS/MS测得替格瑞洛血浆浓度3343 µg/L、活性代谢物AR-C124910XX 656 µg/L,估算摄入剂量约1677 mg。作者认为这是首例同时记录替格瑞洛及其活性代谢物浓度的致死性中毒病例,凸显了针对替格瑞洛过量所致并发症的特异性拮抗剂的必要性。

要点

  • 47岁男性大量摄入替格瑞洛后4天,因跌倒和颅脑创伤继发严重脑出血死亡。
  • 摄入后10小时替格瑞洛血浆浓度3343 µg/L、活性代谢物AR-C124910XX 656 µg/L,估算摄入剂量约1677 mg。
  • 入院后2天ADP诱导血小板聚集、3天血小板VASP磷酸化均显示血小板抑制持续存在。
  • 反复输注血小板未改善病情,作者认为亟需针对替格瑞洛过量的特异性拮抗剂。

适用人群与场景

  • 大量摄入替格瑞洛后发生颅脑创伤的患者

处置流程与药物剂量

  • 对替格瑞洛大量摄入后颅脑创伤患者给予反复血小板输注,但本例未改善病情。

红旗征与不能漏的情况

  • 替格瑞洛大量摄入后发生跌倒和颅脑创伤,可继发严重脑出血并致死。

研究设计与关键结果

  • 病例报告:47岁男性大量摄入替格瑞洛4天后死于跌倒和颅脑创伤继发的严重脑出血;反复输注血小板未改善病情。
  • 摄入后10小时LC-MS/MS测得替格瑞洛血浆浓度3343 µg/L、活性代谢物AR-C124910XX 656 µg/L,估算摄入剂量约1677 mg。
  • 入院后2天ADP诱导血小板聚集、3天血小板VASP磷酸化均显示血小板抑制持续存在。

证据类型、等级与局限

  • 证据类型:病例报告;作者称据其所知此前无同时记录替格瑞洛及其活性代谢物浓度的致死病例报告。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,替格瑞洛过量所致并发症的处理亟需特异性拮抗剂。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ticagrelor is a direct and reversible competitive antagonist of the P2Y12 receptor and inhibits platelet activation. Although adverse bleeding is common, fatal intoxication has never been documented.

CASE DESCRIPTION: A 47-year-old man died from a severe cerebral hemorrhage secondary to a fall and cranial trauma 4 d after the massive intake of ticagrelor. Iterative platelet transfusions did not improve his condition. Toxicological analyses by liquid chromatography tandem mass spectrometry (LC-MS/MS) revealed high plasma concentrations of ticagrelor (3343 µg/L) and its active metabolite AR-C124910XX (656 µg/L) 10 h after intake. The approximate ingested dose was extrapolated to 1677 mg. Assessment of ADP-induced platelet aggregation and platelet Vasodilator Stimulated Phosphoprotein phosphorylation (VASP), 2 and 3 d after admission, respectively, showed the persistence of platelet inhibition.

DISCUSSION: To the best of our knowledge, no prior fatal cases have been reported and documented with both ticagrelor and AR-C124910XX concentrations. Our findings highlight the need for a specific antidote to manage such complications resulting from ticagrelor overdose.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Willeman T, Marlu R, Böhle H, et al. Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed. Clin Toxicol (Phila). 2018. PMID: 29889575. doi:10.1080/15563650.2018.1480026

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。